Retail News Breaks Archives
Study: Children's prescription use for chronic conditions rises
May 20th, 2010
ORLANDO, Fla. – More than one in four insured children in the United States and nearly 30% of 10- to 19-year-olds took at least one prescription medication to treat a chronic condition last year, according to the Medco 2010 Drug Trend Report.
Medco Health Solutions, which announced the report's findings on Wednesday, said that among prescriptions for chronic conditions, the most substantial increases were seen in the use of antipsychotic, diabetes and asthma drugs over the past nine years.
In 2009, drug trend for children — a measure of prescription spending growth — rose 10.8%, driven by a 5% increase in drug utilization and higher medication costs, according to the report. The growth in prescription drug use among children was nearly four times higher than the rise seen in the overall population, Medco noted.
"While H1N1 caused a spike in antiviral use among children last year, the far more alarming trend since the beginning of the decade is the increasing use of medications taken by children on a regular basis and, in some cases, for conditions that we don't often associate with youth, such as type 2 diabetes," Dr. Robert S. Epstein, Medco's chief medical officer and president of the Medco Research Institute, said in a statement.
"The fact that one in three adolescents are being treated for a chronic condition points to the need for additional health education and lifestyle changes that can address the obesity issue that is likely a driving force behind such conditions as type 2 diabetes and even asthma," Epstein added.
Type 2 diabetes medication use by juveniles climbed 5.3% in 2009, the largest increase across all age groups and higher than overall utilization growth of 2.3%, the report found. Since 2001, the number of children ages 19 and younger using these drugs has escalated over 150%, with girls between ages 10 and 19 showing the biggest jump at nearly 200%. Medco noted that although growth in use of these treatments is substantial, the actual number of children using the drugs is still much less than is seen in adults.
The pharmacy benefits provider said the obesity epidemic may also be responsible for a higher prevalence of hypertension and gastroesophageal reflux disease (GERD) in youngsters. From 2001 to 2009, there was a 17% increase in the use of antihypertensives in children, with the greatest growth (29%) seen in boys ages 10 to 19. The number of children on proton pump inhibitors, used to treat heartburn and GERD, and in some cases prescribed for colic in infants, surged by 147% from 2001 to 2009.
The report indicates that utilization and costs of behavioral drug treatments continue to rise in children. In 2009, 13.2% of the prescription drug benefit dollars spent on children went to ADHD treatments. However, the greatest spike in utilization growth last year was not seen in the youngest demographic but in adults aged 20 to 34, where use of these drugs rose 21.2%.
Among the drugs that have experienced substantial gains in the pediatric population are atypical antipsychotics, according to the report. Traditionally used to treat schizophrenia, these drugs have more recently been prescribed for a variety of psychiatric disorders. The nine-year analysis revealed that the use of these treatments in children has doubled over that time period. While atypicals are still more prevalent among boys, the rate of growth (130%) was highest in girls ages 10 to 19.
"Atypical antipsychotics are extremely powerful drugs that are being used far too commonly — especially in children — given their safety issues and side effects," commented Dr. David Muzina, a specialist in mood disorders and national practice leader of the Medco Therapeutic Resource Center for Neuroscience. "We're seeing them prescribed for a number of different conditions, including depression and anxiety, for which there is not good evidence that they are an effective treatment and yet we're exposing children to the possibility of extreme weight gain that could lead to a host of health problems, including diabetes."
Questions of safety did have a major impact on curbing antidepressant use in young people, dropping about 23 percent since 2004 when the FDA issued its strongest safety warnings on the risk of suicidality in children using these medications.
Respiratory drug use grew 5% for children in 2009 and was up 42% since 2001, the Medco drug trend report found. Rising asthma rates accounted for much of the increase, as well as greater awareness of the disease and the importance of early intervention in controlling disease progression. This class of drugs was responsible for the highest proportion of net costs of medications among children.
Children also saw a 46% spike in the use of antiviral drugs, by far the largest increase of all age groups and driven by the high incidence of H1N1 in the young. Children's use was primarily responsible for the 9% rise in utilization for the overall population, the report noted.
Medco added that last year, the Food and Drug Administration expanded to pediatric patients the indications for cholesterol drugs Welchol (colesevalm HCl) and Crestor (rosuvastatin); Atacand (candesartan cilexetil) for hypertension; Axert for migraines; heartburn treatment Protonix (pantoprazole); and atypical antipsychotic medications Abilify (aripriprazole), Seroquel (quetieapine fumarate) and Zyprexa (olanzapine).